Abstract
Background/Aim: Transforming growth factor beta 1 (TGFβ1) is a fibrokine implicated in the progression of renal fibrosis. Following TGFβ1 receptor activation, a number of signalling pathways are stimulated. This study investigates the role of p38 mitogen-activated protein (MAP) kinase and Smad pathways in the TGFβ1-induced fibronectin (FN) production. Methods: Transformed human proximal tubular epithelial cells of the line HKC were used. Secreted FN was analyzed by enzyme-linked immunosorbent assay and Smad proteins by Western blotting. Chemical inhibitors were used to study the role of p38 MAP kinase and the TGFβ receptor ALK5. The Smad pathway was studied using a cell line overexpressing Smad7 and small interfering RNAs (siRNA). The FN mRNA expression was assessed by reverse transcription-polymerase chain reaction. Results: TGFβ1 produced a significant increase in FN secretion in both HKC and Smad7-HKC cells, and the p38 MAP kinase inhibitor SB202190 markedly reduced this (n = 3, p < 0.05 and p < 0.01). ALK5 inhibition also reduced the TGFβ1-induced FN (n = 3, p < 0.05). Smad knockdown using the siRNA did not reduce the TGFβ1-induced FN secretion. TGFβ1 induced FN mRNA expression in HKC cells, and SB202190 decreased this induction (n = 5, p < 0.05). Conclusions: These results suggest that TGFβ1-induced FN production in HKC cells is p38 MAP kinase dependent and Smad independent. Targeting p38 MAP kinase may be of therapeutic value in renal fibrosis.
Journal Section:
Original Paper
References
1.
Viedt C, Burger A, Hansch GM: Fibronectin synthesis in tubular epithelial cells: up-regulation of the EDA splice variant by transforming growth factor beta. Kidney Int 1995;48:1810–1817.
[PubMed]
2.
Burger A, Wagner C, Viedt C, Reis B, Hug F, Hansch GM: Fibronectin synthesis by human tubular epithelial cells in culture: effects of PDGF and TGF-beta on synthesis and splicing. Kidney Int 1998;54:407–415.
[PubMed]
3.
Clark RA: Wound repair. Curr Opin Cell Biol 1989;1:1000–1008.
[PubMed]
4.
Mackensen-Haen S, Bohle A, Christensen J, Wehrmann M, Kendziorra H, Kokot F: The consequences for renal function of widening of the interstitium and changes in the tubular epithelium of the renal cortex and outer medulla in various renal diseases. Clin Nephrol 1992;37:70–77.
[PubMed]
5.
Gharaee-Kermani M, Wiggins R, Wolber F, Goyal M, Phan SH: Fibronectin is the major fibroblast chemoattractant in rabbit anti-glomerular basement membrane disease. Am J Pathol 1996;148:961–967.
[PubMed]
6.
Eddy AA: Molecular insights into renal interstitial fibrosis. J Am Soc Nephrol 1996;7:2495–2508.
[PubMed]
7.
Wilkes MC, Murphy SJ, Garamszegi N, Leof EB: Cell-type-specific activation of PAK2 by transforming growth factor beta independent of Smad2 and Smad3. Mol Cell Biol 2003;23:8878–8889.
[PubMed]
8.
Mauviel A, Chung KY, Agarwal A, Tamai K, Uitto J: Cell-specific induction of distinct oncogenes of the Jun family is responsible for differential regulation of collagenase gene expression by transforming growth factor-beta in fibroblasts and keratinocytes. J Biol Chem 1996;271:10917–10923.
[PubMed]
9.
Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E: Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 1990;346:371–374.
[PubMed]
10.
Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-beta regulates production of proteoglycans by mesangial cells. Kidney Int 1990;37:689–695.
[PubMed]
11.
Bottinger EP, Bitzer M: TGF-beta signaling in renal disease. J Am Soc Nephrol 2002;13:2600–2610.
[PubMed]
12.
Sharma K, Ziyadeh FN, Alzahabi B, McGowan TA, Kapoor S, Kurnik BR, Kurnik PB, Weisberg LS: Increased renal production of transforming growth factor-beta1 in patients with type II diabetes. Diabetes 1997;46:854–859.
[PubMed]
13.
Roberts AB, Derynck R: Meeting report: signaling schemes for TGF-beta. Sci STKE 2001;2001:PE43.
14.
Engel ME, McDonnell MA, Law BK, Moses HL: Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 1999;274:37413–37420.
[PubMed]
15.
Hu PP, Shen X, Huang D, Liu Y, Counter C, Wang XF: The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor-beta. J Biol Chem 1999;274:35381–35387.
[PubMed]
16.
Yamaguchi K, Shirakabe K, Shibuya H, Irie K, Oishi I, Ueno N, Taniguchi T, Nishida E, Matsumoto K: Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270:2008–2011.
[PubMed]
17.
Hocevar BA, Prunier CH, Howe PH: Disabled-2 (Dab2) mediates transforming growth factor beta (TGFbeta)-stimulated fibronectin synthesis through TGFbeta-activated kinase 1 and activation of the JNK pathway. J Biol Chem 2005;280:25920–25927.
[PubMed]
18.
Prakash J, Sandovici M, Saluja V, Lacombe M, Schaapveld R, de Borst M, van Goor H, Henning R, Proost J, Moolenaar F, Keri G, Meijer D, Poelstra K, Kok R: Intracellular delivery of the p38 mitogen-activated protein kinase inhibitor SB202190 [4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)1H imidazole] in renal tubular cells: a novel strategy to treat renal fibrosis. J Pharmacol Exp Ther 2006;319:8–19.
[PubMed]
19.
Isono M, Chen S, Hong SW, Iglesias-de la Cruz MC, Ziyadeh FN: Smad pathway is activated in the diabetic mouse kidney and Smad3 mediates TGF-beta-induced fibronectin in mesangial cells. Biochem Biophys Res Commun 2002;296:1356–1365.
[PubMed]
20.
Heeg MH, Koziolek MJ, Vasko R, Schaefer L, Sharma K, Müller GA, Strutz F: The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int 2005;68:96–109.
[PubMed]
21.
Hocevar BA, Brown TL, Howe PH: TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase dependent, Smad4-independent pathway. EMBO J 1999;18:1345–1356.
[PubMed]
22.
Suzuki H, Uchida K, Nitta K, Nihei H: Role of mitogen-activated protein kinase in the regulation of transforming growth factor-beta-induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin Exp Nephrol 2004;8:188–195.
[PubMed]
23.
Uchiyama-Tanaka Y, Matsubara H, Mori Y, Kosaki A, Kishimoto N, Amano K, Higashiyama S, Iwasaka T: Involvement of HB-EGF and EGF receptor transactivation in TGF-beta-mediated fibronectin expression in mesangial cells. Kidney Int 2002;62:799–808.
[PubMed]
24.
Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA: Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542. Mol Pharmacol 2002;62:58–64.
[PubMed]
25.
Racusen LC, Monteil C, Sgrignoli A, Lucskay M, Marouillat S, Rhim JG, Morin JP: Cell lines with extended in vitro growth potential from human renal proximal tubule: characterization, response to inducers, and comparison with established cell lines. J Lab Clin Med 1997;129:318–329.
[PubMed]
26.
Dai C, Yang J, Liu Y: Transforming growth factor-beta1 potentiates renal tubular epithelial cell death by a mechanism independent of Smad signaling. J Biol Chem 2003;278:12537–12545.
[PubMed]
27.
Phanish MK, Wahab NA, Hendry BM, Dockrell ME: TGF-beta1-induced connective tissue growth factor (CCN2) expression in human renal proximal tubule epithelial cells requires Ras/MEK/ERK and Smad signalling. Nephron Exp Nephrol 2005;100:e156–e165.
28.
Tavian D, De Petro G, Colombi M, Portolani N, Giulini SM, Gardella R, Barlati S: RT-PCR detection of fibronectin EDA+ and EDB+ mRNA isoforms: molecular markers for hepatocellular carcinoma. Int J Cancer 1994;56:820–825.
[PubMed]
29.
Phanish MK, Wahab NA, Colville-Nash P, Hendry BM, Dockrell ME: The differential role of Smad2 and Smad3 in the regulation of pro-fibrotic TGFbeta1 responses in human proximal-tubule epithelial cells. Biochem J 2006;393:601–607.
[PubMed]
30.
Docherty NG, Perez-Barriocanal F, Balboa NE, Lopez-Novoa JM: Transforming growth factor-beta1 (TGF-beta1): a potential recovery signal in the post-ischemic kidney. Ren Fail 2002;24:391–406.
[PubMed]
31.
Dhandapani KM, Brann DW: Transforming growth factor-beta: a neuroprotective factor in cerebral ischemia. Cell Biochem Biophys 2003;39:13–22.
[PubMed]
32.
Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, Motomiya Y, Bucala R, Iida S, Tamaki K, Imaizumi T, Cooper M, Okuda S: AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004;66:2137–2147.
[PubMed]
33.
Huang H, Ma C, Yang M, Tang C, Wang H: Adrenomedullin impairs the profibrotic effects of transforming growth factor-beta1 through recruiting Smad6 protein in human renal tubular cells. Cell Physiol Biochem 2005;15:117–124.
[PubMed]
34.
Stambe C, Atkins RC, Tesch GH, Masaki T, Schreiner GF, Nikolic-Paterson DJ: The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol 2004;15:370–379.
[PubMed]
35.
Yokoi H, Mukoyama M, Sugawara A, Mori K, Nagae T, Makino H, Suganami T, Yahata K, Fujinaga Y, Tanaka I, Nakao K: Role of connective tissue growth factor in fibronectin expression and tubulointerstitial fibrosis. Am J Physiol Renal Physiol 2002;282:F933–F942.
[PubMed]
36.
Inman GJ, Nicolas FJ, Callahan JF, Harling JD, Gaster LM, Reith AD, Laping NJ, Hill CS: SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Mol Pharmacol 2002;62:65–74.
[PubMed]
37.
Tsuchida K, Zhu Y, Siva S, Dunn SR, Sharma K: Role of Smad4 on TGF-beta-induced extracellular matrix stimulation in mesangial cells. Kidney Int 2003;63:2000–2009.
[PubMed]
38.
Piek E, Ju WJ, Heyer J, Escalante-Alcalde D, Stewart CL, Weinstein M, Deng C, Kucherlapati R, Bottinger EP, Roberts AB: Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J Biol Chem 2001;276:19945–19953.
[PubMed]
© 2007 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2007
You do not currently have access to this content.
